{
    "id": 26652,
    "fullName": "NTRK3 G623R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK3 G623R lies within the protein kinase domain of the Ntrk3 protein (UniProt.org). G623R has been demonstrated to occur as a secondary drug resistance mutation in the context of ETV6-NTRK3 (PMID: 28578312, PMID: 26884591), but has not been biochemically characterized and therefore, its effect on Ntrk3 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4916,
        "geneSymbol": "NTRK3",
        "terms": [
            "NTRK3",
            "gp145(trkC)",
            "GP145-TrkC",
            "TRKC"
        ]
    },
    "variant": "G623R",
    "createDate": "06/22/2017",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": {
        "id": 149619,
        "transcript": "NM_001012338",
        "gDna": "chr15:g.87933034C>T",
        "cDna": "c.1867G>A",
        "protein": "p.G623R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15714,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with mammary analogue secretory carcinoma of the salivary gland harboring ETV6-NTRK3 initially responded to Rozlytrek (entrectinib) obtained through a Phase I trial, but her disease progressed and NTRK3 G623R was identified as an acquired mutation at disease progression (PMID: 26884591; NCT02097810).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8850,
                "name": "salivary gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11268,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 and NTRK3 G623R demonstrated a partial response after 28 days when treated with LOXO-195, which continued after 66 days, however, after an additional month progression ensued (PMID: 28578312).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11266,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 progressed on treatment with Vitrakvi (larotrectinib) after 8 months and was found to have acquired NTRK3 G623R (PMID: 28578312).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16328,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 in culture (PMID: 30093503).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15730,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 demonstrated resistance to Vitrakvi (larotrectinib) relative to ETV6-NTRK3 expressing cells in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 demonstrated resistance to Belizatinib (TSR-011) relative to ETV6-NTRK3 expressing cells in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 949,
                "therapyName": "Belizatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15275,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, NTRK3 G623R was identified at disease progression in a pediatric patient with IFS (infantile fibrosarcoma and GIST gastrointestinal stromal tumor) harboring ETV6-NTRK3 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3520,
                "name": "pediatric fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NTRK3 G623R in the context of ETV6-NTRK3 demonstrated resistance to Xalkori (crizotinib) relative to ETV6-NTRK3 expressing cells in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27941,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15274,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK3 G696A and NTRK3 G623R were identified at disease progression in a patient with a gastrointestinal stromal tumor harboring ETV6-NTRK3 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30936,
                "profileName": "ETV6 - NTRK3 NTRK3 G623R NTRK3 G696A"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27940,
            "profileName": "NTRK3 G623R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27941,
            "profileName": "ETV6 - NTRK3 NTRK3 G623R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30936,
            "profileName": "ETV6 - NTRK3 NTRK3 G623R NTRK3 G696A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 149618,
            "transcript": "NM_002530",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149621,
            "transcript": "XM_017022242",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149616,
            "transcript": "XM_017022253",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149617,
            "transcript": "XM_017022254",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149614,
            "transcript": "XM_017022240",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149620,
            "transcript": "XM_006720545",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149619,
            "transcript": "NM_001012338",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 149615,
            "transcript": "XM_006720543",
            "gDna": "chr15:g.87933034C>T",
            "cDna": "c.1867G>A",
            "protein": "p.G623R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}